GlassScriptPhysician profile
Janee' Routh Steele
NPI 1669854964
$4,303.79
in general payments reported to CMS, 2019-2025
23 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $513 · 2021: $363 · 2022: $229 · 2023: $542 · 2024: $1,040 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,106.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $616.05 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $585.93 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $399.57 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $317.42 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.87 | 2019-2025 | Jardiance, Ofev |
| Qol Medical, LLC | $131.34 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $131.17 | 2020-2021 | |
| Amgen INC. | $125.66 | 2019-2025 | Repatha, Otezla, Prolia |
| Exact Sciences Corporation | $87.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $79.66 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $74.91 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $68.87 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $68.01 | 2019-2020 | |
| Pfizer INC. | $60.94 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56.80 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $53.82 | 2025 | Rexulti |
| Shield Therapeutics INC | $46.64 | 2023-2024 | Accrufer |
| Esperion Therapeutics, INC. | $43.17 | 2024-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $31.05 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $17.29 | 2024 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $16.80 | 2025 | |
| Genentech USA, INC. | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janee' Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.